A PYMNTS Company

J&J Must Face Walgreens, Kroger Antitrust Suit Says 3rd Circ.

By  |  February 23, 2020

A US appeals court on Friday, February 21, revived a lawsuit by Walgreen and Kroger accusing Johnson & Johnson (J&J) of unlawfully restricting access to lower-cost “biosimilar” versions of its drug Remicade. 

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Reversing a lower court, the 3rd US Circuit Court of Appeals stated contracts Walgreens and Kroger entered into with drug wholesalers gave the pharmacies the right to sue J&J for antitrust violations.

    The retailers had lodged their suit in Pennsylvania federal court last year, accusing J&J of illegally shielding its blockbuster drug from competitors and charging artificially inflated prices for the treatment. Their suit cited the same core allegations that had sparked earlier legal action from other players in the pharmaceutical industry, including one from rival drugmaker Pfizer and a proposed class suit lodged by other buyers along the Remicade distribution line.

    Full Content: Reuters

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.